Spruce Biosciences Inc (NASDAQ: SPRB) — Perfil da empresa, notícias e dados financeiros
Spruce Biosciences develops novel therapies for rare endocrine disorders, focusing on innovative treatments for patients.
Spruce Biosciences Inc
Spruce Biosciences (NASDAQ:SPRB) focuses on developing novel therapies for rare endocrine disorders. The company is dedicated to advancing treatments that can significantly improve the lives of patients suffering from these conditions. Their primary project centers around tildacerfont, a promising drug candidate aimed at addressing congenital adrenal hyperplasia, a rare disorder impacting the adrenal glands. Spruce Biosciences is committed to pushing the boundaries of medical research to provide new hope for patients with limited treatment options, ultimately aiming to become a beacon of innovation in the rare disease therapeutic space.
Resumo
Operações
Produtos e/ou serviços de Spruce Biosciences Inc
- Development of tildacerfont, a CRF1 receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH).
- Exploration of tildacerfont's potential in treating polycystic ovary syndrome (PCOS).
- Investigation into applications of tildacerfont for patients with Cushing's disease.
- Advanced clinical trials for assessing safety and efficacy of tildacerfont in diverse patient populations.
- Collaborative research initiatives to discover new therapeutic targets within the endocrinology field.
- Partnership programs to enhance drug development and commercialization efficiency.
equipe executiva do Spruce Biosciences Inc
- Michael G. GreyExecutive Chairman
- Javier SzwarcbergCEO & Director
- Samir M. GharibPresident & CFO
- Eric JordanVice President of Marketing
- Bruno GagnonSenior Vice President of Clinical Development Operations
- Daven ModySenior Vice President of Regulatory & Quality
- Corwin Dale HooksChief Commercial Officer
- Adrian QuartelChief Medical Officer
- Saba SileSenior Vice President of Clinical Development
- Tina GullottaVice President of Finance and Corporate Controller
Principais indicadores financeiros
Resultados divulgados pela Spruce Biosciences Inc, em USD.
- Cap. de mercado
- 135 mi
- Receita (TTM)
- 697 mil
- P/L
- —
- LPA (diluído, TTM)
- -39.1
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -36,5 mi | -39 mi | |
| 4,9 mi | -56,2 mi | -53 mi | |
| 10,1 mi | -52 mi | -47,9 mi | |
| 2 mi | -47,3 mi | -46,2 mi |